Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process updated
V
News
First tocilizumab products for Covid-19 prequalified
M
WHO Prequalification Unit (PQT) added the below new products to its prequalified list:
Lab Basi’s paediatric artemether/lumefantrine tablet prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
REGISTRATION OPEN - Joint UNICEF‒UNFPA‒WHO Meeting for Manufacturers and Suppliers
ID
IVD
IS
M
V
VCP
Registration to the (Virtual) Joint UNICEF‒UNFPA‒WHO Meeting for Manufacturers and Suppliers taking place from 08 March to 10 March 2022 is now open.
Ipca’s artemether/lumefantrine tablet prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Guilin’s artemether/lumefantrine tablets prequalified
M
WHO Prequalification Unit (PQT) added the below new products to its prequalified list:
New Invitation for Expression of Interest (EOI) for Active Pharmaceutical Ingredients (APIs) published
M
New Invitation for Expression of Interest (EOI) for Active Pharmaceutical Ingredients (APIs) published
Addition under section:
IVD's Detecting M. Tuberculosis - Coming Soon to PQT
IVD
A Technical Consultation on WHO Prequalification Requirements for Mycobacterium tuberculosis complex (MTBC) NAT assays was held 22-24 November.
Glucose Monitoring Devices - Coming Soon to PQT
IVD
An online information session about the Prequalification of glucose monitoring devices was held for manufacturers on Friday 5 November.
9th Annual Collaborative Registration Procedure
IVD
The 9th annual collaborative registration procedure (CRP) meeting for National Regulatory Authorities (NRAs) was held 13 - 17 December.
Enhancing the Emergency Assessment - Assessors Training
IVD
The In Vitro Diagnostics Assessment Team continues its focus on assessing IVDs for detection of SARS-CoV-2 under the WHO Emergency Use Listing assessment procedure.
Dexamethasone injection prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Nirmatrelvir + ritonavir added to COVID-19 Invitation for Expression of Interest (EOI)
M
Nirmatrelvir 150mg tablets + ritonavir 100mg tablets invited for COVID-19.